About Canepa Healthcare, LLC med-tech-stock

Canepa Healthcare, LLC (“Canepa Healthcare”) is a Securities and Exchange Commission (SEC)-registered investment advisory firm with expertise in global healthcare sector advisory. Canepa Healthcare seeks to identify attractive investment opportunities in companies participating in the global healthcare industry.

Canepa Healthcare serves as the discretionary advisor to its main client, the Canepa Advanced Healthcare Fund, L.P. (“Canepa Advanced Healthcare Fund”). Canepa Healthcare may also provide non-discretionary investment advisory services to other clients. The Canepa Advanced Healthcare Fund is a private investment growth fund that aims to achieve long-term capital appreciation through equity investments primarily in non-public companies that operate in the medical technology (e.g., medical and surgical devices, supplies, and diagnostics) space. It is focused on companies with commercialized products that are in need of growth capital in order to achieve profitability.

Canepa Healthcare has offices in New York and Miami.

Where the Canepa Advanced Healthcare Fund, L.P. Invests

The Canepa Advanced Healthcare Fund, Canepa Healthcare’s primary client, focuses on opportunities within the medical technology sector that meet four main criteria:

poll blue

Stage of investment

The investment objective of the Canepa Advanced Healthcare Fund is to identify healthcare companies with products in the growth stage that have either achieved regulatory clearance or are approaching regulatory approval (where applicable). The fund targets those healthcare companies that can achieve rapid growth for the next 3-5 years.

currency_dollar green

Investment size

The Canepa Advanced Healthcare Fund seeks to invest $5m-$20m into companies with enterprise values of $20m-$200m. The fund is flexible with respect to control versus minority stakes but will only consider situations where there is an opportunity to add value through its active involvement.

pie_chart red


The Canepa Advanced Healthcare Fund focuses less on specific sub-sectors and more on backing world-class teams. However, the fund is currently prioritizing investments in minimally invasive surgery, cardiovascular and trans-catheter technologies, diagnostics, and genomics.

globe blue


While the Canepa Advanced Healthcare Fund will consider investment opportunities across geographies, it is targeting the US and European healthcare markets.



The following companies are a representative sample of the Canepa Advanced Healthcare Fund’s portfolio assets:

Akili Interactive Labs, Inc. is building clinically validated cognitive therapeutics, assessments, and diagnostics that look and feel like high-quality video games. Leveraging medical-grade science and consumer-grade software technology, the company is seeking to produce a new type of healthcare product that is both highly effective and highly engaging. The company was founded by PureTech, a science and technology research and development company, together with leading neuroscientists and game designers.

bioTheranostics, Inc. is a company focused on helping physicians improve the care of cancer patients, offering a suite of proprietary molecular diagnostic tests that allow treatment to be tailored to individual patients. The company’s Breast Cancer IndexSM helps oncologists make difficult decisions about extended endocrine therapy for ER+ breast cancer patients based on its ability to predict risk of late disease recurrence and identify which patients are likely to benefit from continuing therapy beyond five years. Its CancerTYPE ID® is a validated gene expression test for metastatic patients with diagnostic ambiguity, helping physicians determine optimal site-directed treatment regimens with the goal of improving patient outcomes.


Cardiva Medical Inc. is a privately held medical device company that is focused on developing and commercializing innovative vascular closure technology. Cardiva’s VASCADE™ Vascular Closure System was approved by the FDA in 2013 and approved for CE Marking in Europe in 2012. VASCADE is a new generation extravascular closure device designed to increase the comfort and safety of vascular closure for patients. VASCADE utilizes a unique delivery system based on a proprietary collapsible disc technology that provides temporary hemostasis during the procedure which eliminates the need for an intravascular component. Secure and rapid hemostasis is achieved with VASCADE by the deployment of a thrombogenic resorbable collagen patch at the arteriotomy of the femoral artery.


Dune Medical Devices was founded in 2002 to realize the extraordinary medical potential of its proprietary tissue characterization technology. Offering surgeons and radiologists the ability to detect cancer in real time, this technology holds promise for a broad range of diagnostic and therapeutic applications. The company’s first offering, the MarginProbe® System, is now FDA approved and is being used to deliver real-time assessment on excised tissue in breast cancer surgery. A 300-patient randomized study has shown a reduction in re-operation rates by 56% over the standard of care.

Standard Molecular is transforming patient care through integrated genomic data.  Using the Standard Molecular solution, healthcare systems can now leverage genomic data to improve patient care, build stronger patient relationships, and reduce total medical expense.   The company’s proprietary platform enables academic medical centers (AMCs) and accountable care organizations (ACOs) to provide scalable enterprise-wide genomic services that support a wide variety of tests and integrate discrete genomic data into existing clinical systems.

Tryton Medical, Inc., is the developer of novel stent systems designed to treat coronary bifurcation lesions. The Tryton Side Branch Stent System is built for bifurcation using proprietary Tri-ZONE® technology to offer a dedicated strategy for treating bifurcation lesions. Tryton’s cobalt chromium stent is deployed in the side branch artery using a standard single wire balloon-expandable stent delivery system. A conventional drug eluting stent is then placed in the main vessel. The Tryton Side Branch Stent is commercially available in multiple countries within Europe, Middle East & Africa, is investigational in the US, and is not available in Japan.



  • Paul Enever, Ph.D.
    Managing Director

    Paul Enever is a managing director at Canepa Healthcare. Before joining Canepa Healthcare, Paul was a partner at McKinsey and Company. In his 12 years at McKinsey, he advised leading organizations across the bio-pharma, med-tech, hospital, and healthcare services industries primarily in the U.S. and Europe as well as private equity firms specializing in healthcare. Paul’s work focused on growth strategy, sales and marketing, and licensing and acquisition. Previously, Paul worked within the R&D organization at Sandoz Pharmaceuticals and MIT’s Biotechnology Process Engineering Center.

    He sits on the Boards of Directors of Cardiva Medical, Dune Medical Devices, and Standard Molecular.

    Paul has a B.S. in chemical engineering from Rensselaer Polytechnic Institute and a Ph.D. in chemical engineering from the University of Minnesota where he studied wound healing and tissue engineering. For his work, Paul was the recipient of both a National Science Foundation Graduate Fellowship and the Whitaker Foundation Graduate Fellowship in Biomedical Engineering.


  • Alejandro Sanchez
    Managing Director

    Alejandro Sanchez is a managing director at Canepa Healthcare. Prior to joining Canepa Healthcare, he was a co-founder and partner of Hermes Growth Partners, where he launched its Telecom, Media, and Technology Fund. Alejandro is a former partner at McKinsey and Company, where he worked in the telecom, media, and technology sectors across a diverse set of geographies, including Venezuela, Chile, Brazil, Russia, Poland, and the United States.

    He serves on the Boards of Directors of bioTheranostics, Tryton Medical, Virgin Mobile Latin America, WAU and NoShame.

    Alejandro is a systems engineer with an MS in Engineering-Economic Systems from Stanford University.


  • Adam Lessler, M.D.
    Vice President

    Adam Lessler is a vice president at Canepa Healthcare. Prior to joining Canepa Healthcare, Adam was an engagement manager at McKinsey & Company, where he served clients across the health care value chain, with a focus on provider growth and M&A/partnership strategy. Previously, Adam completed his internship in emergency medicine at the Hospital of the University of Pennsylvania and worked as an analyst in the Investment Banking Division at Goldman Sachs and as a research assistant in Harvard Medical School’s Department of Health Care Policy.

    Adam serves as a board observer at bioTheranostics and TPier, Inc. (formerly known as Tute Genomics).

    Adam has a B.A. in economics from Amherst College, an M.B.A. from the Wharton School of the University of Pennsylvania, and an M.D. from the Perelman School of Medicine at the University of Pennsylvania.



Canepa Healthcare, LLC
200 Park Ave South, Suite 1703
New York, NY 10003


To request an offering memorandum and subscription documentation for Canepa Healthcare’s main client, the Canepa Advanced Healthcare Fund, please contact directly:

Canepa Advanced Healthcare Fund, L.P.
Clarendon House, 2 Church Street
Hamilton HM11, Bermuda


Neither Canepa Healthcare, LLC nor Canepa Advanced Healthcare Fund, L.P have any job openings at this time. Neither organization posts open positions through online listings.
The specific investment objectives and the investment strategies of any fund advised by Canepa Healthcare, LLC are described in detail in each respective fund’s offering memorandum and subscription documents or investment management agreement. Material information about a particular fund may be found in the fund’s offering memorandum.

Copyright © 2016 Canepa Healthcare, LLC – Terms of Use

Back to top